Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Clinical Study of the Safety, Tolerability, and Pharmacokinetics of a Single Dose of Brexpiprazole Long-acting Injection in Healthy Subjects/Patients With Schizophrenia.

NCT06674694 is registered in ClinicalTrials.gov with Sichuan Kelun Pharmaceutical Co.,Ltd. as lead sponsor.

NCT NCT06674694
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06674694 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Clinical Study of the Safety, Tolerability, and Pharmacokinetics of a Single Dose of Brexpiprazole Long-acting Injection in Healthy Subjects/Patients With Schizophrenia.
Lead sponsor
Sichuan Kelun Pharmaceutical Co.,Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
April 10, 2024
Completion date
October 30, 2026
Enrollment
56 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia disorders